Pfizer Dostinex (Cabergoline) 0.5mg is a dopamine agonist used to lower elevated prolactin levels and support the treatment of hyperprolactinemia. Each pack contains 8 tablets.
Format8 Tablets
Concentration0.5mg
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Cabergoline, marketed under the pharmaceutical brand name Dostinex and manufactured by Pfizer, is a long acting ergot derived dopamine agonist with FDA approval for hyperprolactinaemia treatment. Contributing one of the most extensively documented clinical literature bases of any prolactin regulating compound, with a well established pharmacokinetic profile spanning several decades of neuroendocrine research. Pfizer’s pharmaceutical manufacturing origin distinguishes this formulation from research grade Cabergoline preparations, providing the quality, purity, and consistency standards of licensed pharmaceutical production. This formulation delivers 0.5mg per tablet in an 8 count pack; a compact format suited to research protocols requiring precise low frequency dosing consistent with Cabergoline’s exceptionally long half-life.
Cabergoline’s half-life of approximately 63 to 68 hours is the defining pharmacokinetic characteristic that distinguishes it from Pramipexole within CSD’s dopamine agonist range. Where Pramipexole requires more frequent administration due to its shorter half-life, Cabergoline’s extended active window enables twice weekly dosing in documented clinical research protocols while maintaining continuous D2 receptor engagement at pituitary lactotroph cells. This prolonged receptor occupancy produces sustained prolactin suppression from infrequent administrations, making Cabergoline the most practically manageable dopamine agonist for extended prolactin regulation research protocols and the most frequently referenced dopaminergic compound in hyperprolactinaemia research literature.
Cabergoline’s D2 receptor selectivity profile differs from Pramipexole’s in a research relevant way. Pramipexole’s exceptionally high D3 receptor affinity alongside D2 activity produces a dual limbic and pituitary dopaminergic research profile. Cabergoline’s primary activity is more specifically concentrated at pituitary D2 receptors producing potent, sustained prolactin suppression with a more targeted neuroendocrine activity profile and less pronounced limbic D3 receptor engagement than Pramipexole. This receptor selectivity distinction makes Cabergoline and Pramipexole complementary rather than interchangeable research tools in comparative dopamine agonist studies. Cabergoline providing the more prolactin focused, long acting pituitary D2 reference compound, Pramipexole providing the shorter acting dual D2/D3 comparative option.
Pfizer Dostinex is stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks both Cabergoline and Pramipexole in the dopamine agonist prolactin regulation range, giving researchers access to both long acting ergot derived and shorter acting non ergot D2/D3 agonist mechanisms from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside Pramipexole in comparative dopamine agonist and prolactin regulation studies. Browse CSD’s full hormone research range for complete sourcing.
Price unbeatable products obviously like amazing pharmaceuticals, straight up and quite the lifesaver cuz I was running into some prolactin issues. Big time. High doses of trend. That'll do it. Thank you! Thank you guys. Save me big on that one. 13 weeks one day for my show. I can't be having issues like that so thank you very much
Dostinex is Pfizer's branded formulation of cabergoline, a prescription ergot derived dopamine receptor agonist. Each scored tablet contains 0.5mg of cabergoline, with 8 tablets supplied per package for 4mg total. Cabergoline acts primarily through dopamine D2 receptors and is best known for its potent and long lasting suppression of prolactin secretion.
Dostinex is used for the treatment of hyperprolactinemic disorders involving abnormally elevated prolactin levels. Depending on regional prescribing information, cabergoline is also used for inhibition or suppression of physiological lactation. Treatment and monitoring should be directed by an appropriate healthcare professional.
Cabergoline directly stimulates dopamine D2 receptors on lactotroph cells in the pituitary gland. Dopamine signaling through these receptors inhibits prolactin secretion, allowing cabergoline to produce substantial and sustained reductions in circulating prolactin concentrations. Its long elimination half-life contributes to the prolonged duration of its prolactin lowering activity.
Dostinex is the original Pfizer brand of cabergoline, while generic cabergoline products contain the same active pharmaceutical ingredient but are manufactured by other companies. Pfizer Dostinex 0.5mg tablets contain cabergoline as the active ingredient and are supplied in branded packaging with Pfizer's specific formulation, manufacturing controls, and product documentation.
Cabergoline can cause postural hypotension and has important warnings involving cardiac valvopathy and fibrotic disorders with long term use. Pfizer's prescribing information recommends cardiovascular assessment, including echocardiography, before prolonged therapy and continued monitoring when clinically appropriate. Cabergoline has also been associated with somnolence and impulse control disorders and should be used under appropriate medical supervision.
